Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
about
Hepatitis C virus infection protein networkCirrhosis: new research provides a basis for rational and targeted treatmentsAntiviral therapy of HCV in the cirrhotic and transplant candidate.Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseKASL clinical practice guidelines: management of hepatitis CChronic hepatitis C: This and the new era of treatmentClinical Advances in Fibrosis Progression of Chronic Hepatitis B and CPotential Role of the Gut/Liver/Lung Axis in Alcohol-Induced Tissue PathologyHepatitis C: Treatment of difficult to treat patientsHepatitis C cirrhosis: New perspectives for diagnosis and treatmentPrediction of fibrosis progression in chronic viral hepatitisChronic hepatitis C and liver fibrosis.Future classes of hepatitis C virus therapeutic agentsReversibility and heritability of liver fibrosis: Implications for research and therapyProphylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infectionThe Role of Obstetrician/Gynecologists in the Management of Hepatitis C Virus InfectionA dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patientsSustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibodyClinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patientsSocio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional surveyAntiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated conditionMolecular mechanism and treatment of viral hepatitis-related liver fibrosis.Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver InjuryHepatic steatosis and fibrosis: Non-invasive assessment.Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesA novel solid-phase site-specific PEGylation enhances the in vitro and in vivo biostabilty of recombinant human keratinocyte growth factor 1Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis CModeling the Health and Economic Burden of Hepatitis C Virus in SwitzerlandFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Automated liver elasticity calculation for MR elastographyNon-invasive evaluation of liver stiffness after splenectomy in rabbits with CCl4-induced liver fibrosisHepatitis C treatment: where are we now?Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.Automated liver stiffness measurements with magnetic resonance elastography.Review of MR elastography applications and recent developments.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Evolving therapies for liver fibrosis.
P2860
Q24311906-DCA7065B-EAE8-432D-8BEE-2153D83C75C7Q24527263-88591B8C-D4CB-4F17-8339-70B356AE82AFQ24541565-489BD09E-731B-4ADE-9932-0E9EC22FB59FQ26752433-F6AC1480-3C1C-41FB-A637-7377617D25E3Q26752471-5F73776C-784F-4B8A-8EB8-9F9D7BCA9E9EQ26775011-403283F1-7940-46A4-AE4C-22C6A314E806Q26781789-9B02B757-3E17-4E95-8B3A-9B31FBFED9A6Q26781989-E3CA7CBE-2A2D-4D93-8C9B-DD7BDF35FA07Q26798465-F2AF0771-C051-4669-ABCE-646C536628A9Q26799924-65A94D44-4589-4AFD-8305-4AA261B621AAQ26823671-9F8EF512-8263-420B-803F-AA06C9AEA41BQ26825671-7597DFCB-AA9E-4593-AC09-5E5DAED1FB64Q27009321-B0361B05-A205-4504-91CB-F5F976D07028Q27026622-791FC221-46D4-477F-9FEF-57881BCFE3EDQ27478125-97A6ECF9-9FD4-4E69-9A7F-32DDC7E5FCB1Q27486939-651F22E8-03B7-4A76-A7FB-C31B87F4A146Q27488742-A33588BC-69F9-4B91-BA6A-B24276088A33Q27488912-3C735EA4-2BF6-460E-B98D-9B16477CF962Q27489398-91B2A4E1-9FB1-4091-9DFE-3602E4133A72Q27490161-260FA7AF-0A43-4464-A2A9-58B615CF301CQ27490340-00BB0E33-DA53-4CC2-BBDB-75BA08CFE8E3Q27692609-3C1AEAA3-E8E3-4D9F-81A6-1AD4BA0768B5Q28071500-9CD909A3-997A-42C9-9D14-899FBE7619B5Q28077200-42D29AA2-3781-4EDB-82C5-17DABB5C3774Q28272678-138803DD-A2E7-42F8-9517-638606C41787Q28483340-CEA65761-A7CA-4539-869C-C93310F62C0AQ28540562-E2B626AC-CAE9-4C86-A02D-C1B58E9A6998Q28548657-BE99F88F-F693-4AE1-908A-98CA13F092A6Q30235178-5F688F4C-1DB4-482E-B653-818DDE7E2090Q30250088-918BD877-F256-49E4-9D99-5386E16D456DQ30250096-DDB23975-0BC1-488B-ADE9-66573F4FF221Q30250322-1AA17DA6-94A9-4A63-AB32-3994BB330460Q30357722-B090DBF0-3289-4C32-BB5A-61D8ED8F268DQ30367357-AA704B79-38A4-4AA3-8131-306508AA22AEQ30378509-E79BCBDA-7D9B-4DF0-823E-E399E6F6E03DQ30402571-0B05770B-BE45-4558-9169-C66B2ACE1E8AQ30433801-50A2B549-05C0-4AEB-BF4D-54277999065EQ30448711-F46178F5-10D9-4FF9-9669-BC4063156363Q30453975-6A9B8EDA-CEE4-49C1-94C8-14DE3A07DD3AQ30539166-73563B19-3250-4254-9AFE-F507405D859A
P2860
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Impact of pegylated interferon ...... ents with chronic hepatitis C.
@en
Impact of pegylated interferon ...... ents with chronic hepatitis C.
@nl
type
label
Impact of pegylated interferon ...... ents with chronic hepatitis C.
@en
Impact of pegylated interferon ...... ents with chronic hepatitis C.
@nl
prefLabel
Impact of pegylated interferon ...... ents with chronic hepatitis C.
@en
Impact of pegylated interferon ...... ents with chronic hepatitis C.
@nl
P2093
P356
P1433
P1476
Impact of pegylated interferon ...... ents with chronic hepatitis C.
@en
P2093
Christian Trepo
Janice Albrecht
John McHutchison
Karen Lindsay
Mei-Hsiu Ling
Michael Manns
Zachary Goodman
P304
P356
10.1053/GAST.2002.33023
P407
P577
2002-05-01T00:00:00Z